antith (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
96
Structured Review
Santa Cruz Biotechnology
antith
Antith, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 490 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antith+antibody/TH+Antibody/pm39227736-191-20-23
Average 96 stars, based on 490 article reviews
Antith, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 490 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antith+antibody/TH+Antibody/pm39227736-191-20-23
Average 96 stars, based on 490 article reviews
antith - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Blocking Assay:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Next-Generation Sequencing:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Concentration Assay:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Microscopy:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Software:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Comparison:Article Title: Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. Article Snippet: One potential complication of treating Parkinson’s Disease (PD) with dopaminergic drugs is dopamine dysregulation syndrome, an addiction-like response to the drug therapy.. Here, we assessed whether rats given parkinsonian-like symptoms with a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle (6-OHDA-MFB), exhibit similar behavior.. To examine this, we injected these rats or sham-lesioned rats subcutaneously (sc) with apomorphine (APO) at low (0.05 mg/kg) and high (1 mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days. Incubation:Article Title: Inhibition of the fatty acid amide hydrolase changes behaviors and brain catecholamines in a sex-specific manner in rats exposed to chronic unpredictable stress. Article Snippet: Sex differences in the susceptibility to chronic unpredictable stress (CUS) and the effects of fatty acid amide hydrolase (FAAH) inhibitor URB597 in rats have been investigated in this study.. In this context, we investigated the effects of prolonged treatment with URB597 on behavior, pro-inflammatory interleukin-6 (IL-6) and antiinflammatory interleukin-10 (IL-10), catecholamine content and the expression of its biosynthetic and degrading enzymes in the hippocampus, hypothalamus and medial prefrontal cortex (mPFC) of rats subjected to CUS.. The results show that CUS increases anxiety-like and depression-like behaviors but it was more pronounced in females. |